의료 영상 분석 소프트웨어 시장 : 컴포넌트별, 영상 진단법별, 도입 형태별, 영상 차원별, 용도별, 최종 사용자별 시장 예측(2026-2032년)

The Medical Image Analysis Software Market is projected to grow by USD 6.86 billion at a CAGR of 7.95% by 2032.

Medical image analysis software has become a critical layer of modern diagnostic imaging, connecting radiology, cardiology, oncology, pathology, neurology, orthopedics, and surgical planning workflows. Demand is supported by measurable disease burden: the World Health Organization reports that noncommunicable diseases account for about 74% of global deaths, while IARC estimated roughly 20 million new cancer cases worldwide in 2022. These trends keep imaging volumes high and increase the need for faster interpretation, standardized quantification, and enterprise-scale workflow orchestration.

The market is shifting from point tools toward cloud-enabled, interoperable platforms that integrate with PACS, VNA, RIS, EHR, DICOM, HL7, and FHIR environments. Vendors that can demonstrate clinical validation, regulatory readiness, cybersecurity controls, explainable outputs, and measurable productivity gains are best positioned as providers seek safer throughput, earlier detection, and consistent reporting across distributed care networks.

Transformative Shifts in the Market Landscape

The landscape is being reshaped by enterprise imaging, cloud deployment, value-based care, and radiology workforce constraints. Hospitals are prioritizing tools that reduce repetitive measurements, flag urgent findings, support structured reporting, and make images accessible across care settings. This is especially important as health systems consolidate imaging operations, expand teleradiology coverage, and adopt centralized reading models.

Regulation is also becoming more sophisticated. The FDA's public list of AI/ML-enabled medical devices shows radiology as the leading specialty for authorized AI tools, confirming imaging as the most mature clinical AI category. At the same time, the EU Medical Device Regulation, the EU AI Act, GDPR, and global SaMD guidance are raising expectations for risk management, post-market monitoring, explainability, clinical evaluation, cybersecurity, and real-world performance evidence.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is creating cumulative impact across image acquisition, reconstruction, segmentation, detection, triage, quantification, and follow-up comparison. In practice, AI-enabled medical imaging software is most valuable when it shortens turnaround time, improves consistency, highlights subtle abnormalities, and automates labor-intensive tasks such as lesion measurement, organ segmentation, cardiac function assessment, and longitudinal disease tracking.

However, adoption depends on more than algorithm accuracy. Buyers increasingly evaluate bias testing, local population validation, integration burden, cybersecurity, audit trails, model monitoring, and clinician oversight. The strongest AI solutions are not replacing radiologists or specialists; they are augmenting clinical teams with decision support that fits existing workflows, supports quality assurance, and generates measurable operational value.

Key Regional Insights

North America remains a leading region due to mature hospital IT infrastructure, broad PACS penetration, strong adoption of advanced imaging, and a clear FDA framework for AI/ML-enabled devices. The United States and Canada benefit from established academic medical centers, integrated delivery networks, and rising use of enterprise imaging across radiology, cardiology, and oncology. Europe combines high imaging standards with stricter compliance requirements under MDR, GDPR, and the EU AI Act, making evidence generation, data protection, interoperability, and clinical governance central to commercialization.

Asia-Pacific is expanding rapidly as China, Japan, India, South Korea, and Australia invest in digital health, cancer screening, hospital modernization, and AI-enabled diagnostic capacity. Latin America is led by Brazil and Mexico, where private hospital networks, diagnostic center expansion, and teleradiology are supporting adoption despite infrastructure variability. The Middle East, particularly GCC markets, is investing in smart hospitals, national health transformation programs, and high-acuity imaging services, while Africa's opportunity is linked to teleradiology, mobile imaging, cloud access, and solutions that address radiologist shortages and uneven specialist availability.

Key Group Insights

ASEAN markets are advancing through digital health strategies, expanding private healthcare capacity, and cross-border interest in cloud-based imaging workflows that can support multi-site hospital groups. The GCC is notable for national transformation programs, large hospital investments, and demand for high-acuity imaging in oncology, cardiology, trauma, and preventive care. The European Union is shaped by harmonized regulation, privacy requirements, MDR compliance, and the emerging European Health Data Space, which supports trusted health data exchange and secondary use under structured safeguards.

BRICS countries represent large imaging volumes and growing domestic innovation, especially in China, India, and Brazil, where access expansion and public-private healthcare investment influence adoption priorities. G7 markets remain influential because they set clinical adoption patterns, procurement expectations, reimbursement discussions, and regulatory precedents for AI-enabled medical imaging software. NATO members add a resilience dimension, emphasizing secure infrastructure, cyber protection, data sovereignty, and continuity of diagnostic imaging services in complex operating environments.

Key Country Insights

The United States leads commercialization through FDA-cleared AI imaging tools, large academic medical centers, integrated delivery networks, and enterprise imaging procurement. Canada emphasizes quality, privacy, provincial health system integration, and equitable access across geographically dispersed populations, while Mexico is expanding private imaging capacity and specialist-led diagnostic services. Brazil is Latin America's largest healthcare market and a key adopter of teleradiology, advanced diagnostics, and hospital-based digital imaging workflows.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are prioritizing digital radiology modernization under strict data protection and medical device rules, with procurement increasingly focused on workflow efficiency, clinical validation, and interoperability. Russia maintains demand through large hospital networks and continued need for diagnostic modernization. China is scaling AI imaging through domestic software innovation, hospital digitization, and high imaging volumes; India is driven by access gaps, high scan volumes, and the need for scalable decision support. Japan and South Korea emphasize precision diagnostics, robotics, advanced imaging, and AI-enabled hospital systems, while Australia supports adoption through mature digital health infrastructure and geographically distributed care needs.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated solutions that solve measurable workflow problems, not isolated algorithm demonstrations. Successful commercialization requires evidence on sensitivity, specificity, turnaround time, reader productivity, false-positive burden, usability, health equity, and downstream clinical value. Partnerships with hospitals, radiology groups, specialty societies, and academic centers can accelerate real-world validation and trust.

Executives should also build for interoperability, cybersecurity, and lifecycle governance from the start. This means supporting DICOM, HL7, FHIR, enterprise identity controls, auditability, role-based access, model monitoring, version control, and transparent update pathways. Companies that align product roadmaps with FDA, EU, and IMDRF expectations will be better prepared for procurement reviews, post-market obligations, and long-term deployment.

Research Methodology

This executive summary is based on a structured review of public regulatory frameworks, global health burden data, healthcare digitization trends, and established medical imaging technology standards. Key reference points include WHO and IARC disease burden reporting, FDA AI/ML-enabled device communications, IMDRF SaMD principles, EU MDR and EU AI Act requirements, GDPR, and widely adopted interoperability standards such as DICOM, HL7, and FHIR.

The analysis emphasizes verified market signals rather than speculative projections. Regional, group, and country insights were developed by comparing healthcare infrastructure maturity, regulatory direction, imaging demand, digital health investment, workforce constraints, data governance requirements, and adoption barriers across major markets.

Conclusion

Medical image analysis software is moving from departmental efficiency tool to strategic diagnostic infrastructure. The strongest opportunities are tied to AI-assisted interpretation, enterprise imaging, cloud deployment, automated quantification, structured reporting, secure data exchange, and integrated decision support across care networks.

As adoption expands, the winners will be organizations that combine regulatory discipline, clinical evidence, seamless integration, cybersecurity maturity, and measurable workflow impact. In an environment shaped by rising disease burden, imaging volume growth, specialist shortages, and operational pressure, trusted medical image analysis platforms will play a central role in improving diagnostic speed, consistency, quality, and access.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Medical Image Analysis Software Market, by Component

• 7.1. Services
• 7.2. Software

8. Medical Image Analysis Software Market, by Imaging Modality

• 8.1. Computed Tomography
• 8.2. Magnetic Resonance Imaging
• 8.3. Nuclear Imaging
• 8.4. Ultrasound
• 8.5. X-Ray

9. Medical Image Analysis Software Market, by Deployment Mode

• 9.1. Cloud
• 9.2. On-Premises

10. Medical Image Analysis Software Market, by Image Dimensionality

• 10.1. 2D Imaging
• 10.2. 3D Imaging
• 10.3. 4D Imaging

11. Medical Image Analysis Software Market, by Application

• 11.1. Cancer Detection
  • 11.1.1. Breast Cancer
  • 11.1.2. Lung Cancer
  • 11.1.3. Prostate Cancer
• 11.2. Cardiovascular Imaging
  • 11.2.1. Cardiac Mri Analysis
  • 11.2.2. Coronary Artery Disease Detection
  • 11.2.3. Echocardiography Analysis
• 11.3. Neurological Analysis
• 11.4. Orthopedic Analysis

12. Medical Image Analysis Software Market, by End User

• 12.1. Academic And Research Institutes
• 12.2. Diagnostic Centers
• 12.3. Hospitals
• 12.4. Imaging Centers
• 12.5. Pharmaceutical & Biotechnological Firms

13. Medical Image Analysis Software Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Medical Image Analysis Software Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Medical Image Analysis Software Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Agfa-Gevaert N.V.
• 17.2. AnalyzeDirect, Inc.
• 17.3. AQUILAB SAS
• 17.4. Arterys, Inc.
• 17.5. Blackford Analysis Ltd.
• 17.6. Canon Medical Systems Corporation
• 17.7. Carestream Health, Inc.
• 17.8. Circle Cardiovascular Imaging Inc.
• 17.9. ContextVision AB
• 17.10. Esaote S.p.A.
• 17.11. Fujifilm Holdings Corporation
• 17.12. GE HealthCare Technologies Inc.
• 17.13. Image Analysis Group Ltd.
• 17.14. INFINITT Healthcare Co., Ltd.
• 17.15. International Business Machines Corporation
• 17.16. Kitware, Inc.
• 17.17. Koninklijke Philips N.V.
• 17.18. Lunit Inc.
• 17.19. Mach7 Technologies Ltd.
• 17.20. Medis Medical Imaging Systems BV
• 17.21. MIM Software Inc.
• 17.22. Novarad Corporation
• 17.23. QMENTA, Inc.
• 17.24. ScienceSoft USA Corporation
• 17.25. Sectra AB
• 17.26. Siemens Healthineers AG
• 17.27. TeraRecon, Inc.
• 17.28. Visage Imaging GmbH
• 17.29. Xinapse Systems Ltd.
• 17.30. Ziosoft, Inc.